← Past results34 of 63 · Past edition
PoliticsAugust 23, 2026
Should deals for pending drug-patent rights face antitrust review like patent purchases?
Review may prevent companies from using pending applications to extend a monopoly. Drug makers may argue that legitimate rights agreements support investment and predictable development.
A clear snapshot, not a scientific poll.
SidePick results reflect votes cast by site visitors. They are an informal public-opinion snapshot and should not be treated as representative polling. The first vote from each device is final for that debate.
SidePick is independent and is not affiliated with any person, campaign, party, government body, or organization referenced in this debate.
Say why you picked your side.
Be civil. No threats, harassment, spam, links, or personal information. Repeatedly reported comments are automatically hidden. Read the community guidelines.